This overview of the safety of becaplermin gel is based on six well-controlled clinical studies
that included patients with lower extremity diabetic neuropathic ulcers. Patients receiving
becaplermin gel (n= 538), placebo gel (n= 278), or good ulcer care alone (n= 190) had a
similar incidence of ulcer-related adverse events, such as infection, cellulitis, or
osteomyelitis. Erythematous rash occurred in 2% of patients with suspected wound
infections treated with becaplermin gel and 1% of patients treated with placebo gel. No …